Press Releases September 1, 2026 07:00 AM

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Tango Therapeutics Announces Participation in 2026 Cantor Global Healthcare Conference Fireside Chat

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
TNGX

Tango Therapeutics, a clinical-stage biotech company focused on precision oncology therapies, will present at the 2026 Cantor Global Healthcare Conference. The company is advancing cancer treatments through synthetic lethality targets and will webcast its management discussion.

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
TNGX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Tango Therapeutics is a clinical-stage biotechnology company developing precision medicines for cancer treatment.
  • The company leverages synthetic lethality to discover novel drug targets critical to cancer.
  • Tango will participate in a widely followed global healthcare conference with a live and replay webcast accessible to investors.

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT.

The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.

Investors:
Elizabeth Hickin
[email protected]

Media:
1AB
Amanda Lazaro
[email protected]


Risks

  • As a clinical-stage biotech, Tango is subject to risks related to drug development timelines and regulatory approvals.
  • Market and investor response can be sensitive to presentation details and clinical progress updates.
  • The oncology biotechnology sector is competitive and dependent on scientific breakthroughs and patent protections.

More from Press Releases

Zhihu Inc. Announces Proposed Subscription in AI-Focused Investment Fund Sep 6, 2026 Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call Sep 6, 2026 Verizon Waives Charges for Hurricane Lowell, Prepares Network in Hawai'i Sep 5, 2026 Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen Sep 4, 2026 Grupo Aeroportuario del Pacifico Reports a Passenger Traffic Increase in August 2026 of 0.5% Compared to 2025 Sep 4, 2026